Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2026, HAEMONETICS CORPORATION reported revenue of $1.33B, down 2.0% year over year. Operating margin was 11.7% and net margin 7.3%, on a free-cash-flow margin of 19.5% with capital expenditure at 2.5% of revenue. Every figure is computed directly from HAE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $1.33B | 11.7% | 7.3% |
| FY2025 | $1.36B | 16.3% | 12.3% |
| FY2024 | $1.31B | 12.6% | 9.0% |
| FY2023 | $1.17B | 13.4% | 9.9% |
| FY2022 | $993M | 8.1% | 4.4% |
How does HAE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.